DE60131498D1 - VIRUS-HüLLENVEKTOR FüR GENTRANSFER - Google Patents

VIRUS-HüLLENVEKTOR FüR GENTRANSFER

Info

Publication number
DE60131498D1
DE60131498D1 DE60131498T DE60131498T DE60131498D1 DE 60131498 D1 DE60131498 D1 DE 60131498D1 DE 60131498 T DE60131498 T DE 60131498T DE 60131498 T DE60131498 T DE 60131498T DE 60131498 D1 DE60131498 D1 DE 60131498D1
Authority
DE
Germany
Prior art keywords
gentransfer
cover vector
virus cover
virus
vector
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60131498T
Other languages
English (en)
Other versions
DE60131498T8 (de
DE60131498T2 (de
Inventor
Yasufumi Kaneda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anges Inc
Original Assignee
Anges MG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges MG Inc filed Critical Anges MG Inc
Publication of DE60131498D1 publication Critical patent/DE60131498D1/de
Application granted granted Critical
Publication of DE60131498T2 publication Critical patent/DE60131498T2/de
Publication of DE60131498T8 publication Critical patent/DE60131498T8/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16663—Methods of inactivation or attenuation by chemical treatment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18823—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18861—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18811—Sendai virus
    • C12N2760/18861—Methods of inactivation or attenuation
    • C12N2760/18863—Methods of inactivation or attenuation by chemical treatment
DE60131498T 2000-02-02 2001-02-02 VIRUSHÜLLENVEKTOR FüR DIE GENÜBERTRAGUNG Active DE60131498T8 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000025596 2000-02-02
JP2000025596 2000-02-02
PCT/JP2001/000782 WO2001057204A1 (fr) 2000-02-02 2001-02-02 Vecteur d'enveloppe virale pour transfert de gene

Publications (3)

Publication Number Publication Date
DE60131498D1 true DE60131498D1 (de) 2008-01-03
DE60131498T2 DE60131498T2 (de) 2008-10-02
DE60131498T8 DE60131498T8 (de) 2009-01-29

Family

ID=18551433

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60131498T Active DE60131498T8 (de) 2000-02-02 2001-02-02 VIRUSHÜLLENVEKTOR FüR DIE GENÜBERTRAGUNG

Country Status (10)

Country Link
US (3) US6913923B2 (de)
EP (1) EP1170363B1 (de)
KR (2) KR100847385B1 (de)
CN (3) CN100532559C (de)
AU (1) AU769385C (de)
CA (1) CA2369491C (de)
DE (1) DE60131498T8 (de)
HK (1) HK1047449A1 (de)
TW (1) TWI303663B (de)
WO (1) WO2001057204A1 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100847385B1 (ko) * 2000-02-02 2008-07-18 안제스에무지 가부시키가이샤 유전자 전달을 위한 바이러스 엔벨로프 벡터
EP1297852A4 (de) * 2000-06-27 2004-12-29 Dnavec Research Inc Viraler vektor zur einbringung von genen in nierenzellen(03.02.03)
EP1690544B1 (de) * 2001-02-20 2017-09-13 AnGes MG, Inc. Pharmazeutische Zusammensetzungen mit einem Decoy und Verfahren zu ihrer Verwendung
WO2003014338A1 (fr) * 2001-08-02 2003-02-20 Anges Mg, Inc. Procede de production d'enveloppes virales inactivees
JPWO2003029475A1 (ja) * 2001-09-28 2005-01-20 株式会社ディナベック研究所 エピトープ結合β２ｍをコードする哺乳動物細胞感染性ウイルスベクターおよびその利用
DE60231063D1 (de) 2002-02-01 2009-03-19 Anges Mg Inc N zur behandlung von aneurysmen
CA2490357A1 (en) * 2002-06-06 2003-12-18 Anges Mg, Inc. Gene therapeutic for cerebrovascular disorders
EP1535993A4 (de) * 2002-08-27 2007-03-21 Anges Mg Inc VERFAHREN ZUR ÜBERTRAGUNG VON BIOMOLEKüLEN UNTER VERWENDUNG DER VIRUSHÜLLE SOWIE ZUSAMMENSETZUNG UND SYSTEM DAFüR
EP1559780A1 (de) * 2002-10-01 2005-08-03 Dnavec Research Inc. Verfahren zur verstärkung der fremdepitop-präsentation mit mhc klasse i mittels hemmung der tap-aktivität
AU2003280604A1 (en) 2002-11-01 2004-05-25 Anges Mg, Inc. Medicinal preparation having chemotherapeutic encapsulated therein
CA2506894A1 (en) * 2002-11-21 2004-06-03 Genomidea Inc. Method of isolating nucleic acid having desired functional property and kit therefor
JP2004289816A (ja) * 2003-03-06 2004-10-14 Matsushita Electric Ind Co Ltd 遠隔制御装置、遠隔制御方法および被遠隔制御装置
WO2005094878A1 (ja) 2004-03-31 2005-10-13 Genomidea Inc. 抗腫瘍作用を有する組成物
NZ550430A (en) 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
ES2357772T3 (es) 2004-06-14 2011-04-29 Ishihara Sangyo Kaisha, Ltd. Composición liofilizada de envuelta viral inactivada con actividad de fusión de membrana.
WO2007011601A2 (en) * 2005-07-14 2007-01-25 Wellstat Biologics Corporation Cancer treatment using viruses, fluoropyrimidines and camptothecins
US20090214496A1 (en) * 2006-01-30 2009-08-27 Licentia Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
WO2007088882A1 (ja) 2006-01-31 2007-08-09 Ishihara Sangyo Kaisha, Ltd. エンベロープウイルスの構成成分に親和性を有するポリペプチドと細胞内物質導入への使用
JP2008308440A (ja) * 2007-06-14 2008-12-25 Genomidea Inc 癌治療用薬剤送達ビヒクルおよびその製造方法ならびにそれを用いた製剤
WO2010032764A1 (ja) 2008-09-16 2010-03-25 ジェノミディア株式会社 前立腺癌の治療・予防剤
US8927493B2 (en) 2008-10-10 2015-01-06 Kringle Pharma, Inc. Promoter for regeneration of tendon-bone junction tissue or ligament-bone junction tissue
WO2011046983A2 (en) 2009-10-12 2011-04-21 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
JP4653242B1 (ja) 2010-02-12 2011-03-16 ナノキャリア株式会社 粒子状医薬組成物
BR112012027643A2 (pt) * 2010-05-03 2016-08-16 Glaxosmithkline Biolog Sa métodos para a inativação de um orthomixovírus, para a preparação de uma vacina, e , composição imunogênica
CN103941924B (zh) * 2014-04-25 2016-09-14 锐达互动科技股份有限公司 一种实现红外光编解码的互动投影方法
EP3536329B1 (de) 2016-11-01 2022-08-31 Osaka University Antikrebsmittel mit hvj-e und neutralisierenden antikörpers gegen pd-1
US11413477B2 (en) * 2016-11-22 2022-08-16 Cedars-Sinai Medical Center Transfection and drug delivery
ES2896255T3 (es) 2016-12-06 2022-02-24 Univ Osaka Nuevo agente terapéutico para enfermedades por prionoides
WO2022059703A1 (ja) 2020-09-16 2022-03-24 国立大学法人大阪大学 がん治療用医薬、免疫賦活剤および抗がん物質のスクリーニング方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2961658D1 (en) 1978-05-17 1982-02-18 Thomae Gmbh Dr K Process for preparing human interferon
CA1282721C (en) * 1984-06-04 1991-04-09 Bernard Roizman Herpes simplex virus as a vector
EP0555333B1 (de) * 1990-10-19 1995-12-27 University Of Florida Künstliche virushüllen
US5879685A (en) * 1991-05-08 1999-03-09 Schweiz, Serum- & Impfinstitut Bern Immunostimulating and immunopotentiating reconstituted influenza virosomes and vaccines containing them
US6268213B1 (en) 1992-06-03 2001-07-31 Richard Jude Samulski Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy
US5244635A (en) 1992-06-19 1993-09-14 Cirrus Diagnostics, Inc. Centrifuge vessel with coaxial waste chamber having cap to prevent waste fluid transfer from the chamber into the vessel
US5578475A (en) * 1993-07-12 1996-11-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
FR2713657B1 (fr) * 1993-12-13 1996-03-01 Transgene Sa Nouveaux vecteurs pour le traitement du sida.
US5843459A (en) 1996-01-19 1998-12-01 Human Gene Therapy Research Institute Differential inactivation of nucleic acids by chemical modification
JP3744583B2 (ja) * 1996-03-01 2006-02-15 株式会社ディナベック研究所 遺伝子導入用組成物及び該組成物を用いた遺伝子導入方法
US6451592B1 (en) * 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
US5683866A (en) * 1996-05-09 1997-11-04 Sarkar; Debi P. Process for producing a targeted gene
US6183752B1 (en) * 1997-02-05 2001-02-06 Pasteur Merieux Serums Et Vaccins Restenosis/atherosclerosis diagnosis, prophylaxis and therapy
US6051428A (en) * 1997-03-21 2000-04-18 Sloan-Kettering Institute For Cancer Research Rapid production of autologous tumor vaccines
US5849561A (en) 1997-05-22 1998-12-15 Cornell Research Foundation, Inc. Method for the production of non-group C adenoviral vectors
US6432925B1 (en) 1998-04-16 2002-08-13 John Wayne Cancer Institute RNA cancer vaccine and methods for its use
US6472375B1 (en) * 1998-04-16 2002-10-29 John Wayne Cancer Institute DNA vaccine and methods for its use
WO2000028020A2 (en) * 1998-11-10 2000-05-18 Board Of Regents, The University Of Texas System Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
KR100847385B1 (ko) 2000-02-02 2008-07-18 안제스에무지 가부시키가이샤 유전자 전달을 위한 바이러스 엔벨로프 벡터
US6509162B1 (en) * 2000-02-29 2003-01-21 Yale University Methods for selectively modulating survivin apoptosis pathways

Also Published As

Publication number Publication date
EP1170363A1 (de) 2002-01-09
EP1170363A4 (de) 2002-06-12
EP1170363B1 (de) 2007-11-21
US20030013195A1 (en) 2003-01-16
AU769385C (en) 2004-07-29
US7279333B2 (en) 2007-10-09
HK1047449A1 (zh) 2003-02-21
AU769385B2 (en) 2004-01-22
CA2369491A1 (en) 2001-08-09
AU3057801A (en) 2001-08-14
KR20070059182A (ko) 2007-06-11
KR100847385B1 (ko) 2008-07-18
CN1657103A (zh) 2005-08-24
US20050239188A1 (en) 2005-10-27
CN100542614C (zh) 2009-09-23
US20040219674A1 (en) 2004-11-04
CN101302536A (zh) 2008-11-12
KR20020004987A (ko) 2002-01-16
US6913923B2 (en) 2005-07-05
CA2369491C (en) 2008-09-02
WO2001057204A1 (fr) 2001-08-09
US7803621B2 (en) 2010-09-28
KR100776475B1 (ko) 2007-11-16
CN1365388A (zh) 2002-08-21
DE60131498T8 (de) 2009-01-29
CN100532559C (zh) 2009-08-26
TWI303663B (en) 2008-12-01
DE60131498T2 (de) 2008-10-02

Similar Documents

Publication Publication Date Title
DE60131498D1 (de) VIRUS-HüLLENVEKTOR FüR GENTRANSFER
DE60107557D1 (de) Dosendeckel
DE60235192D1 (de) Abdeckung
DE60116209D1 (de) Airbagabdeckung
DE50100900D1 (de) Fixierelement
DE60219045D1 (de) Wiederverschliessbarer behälterdeckel
DE60124596D1 (de) Durchgangstülle
DE60206017D1 (de) Abdeckung für bohrlochfilter
DE60105809D1 (de) Dosendeckel
DE60100848D1 (de) Virtuelles rom für geräte-aufzählung
DE60138843D1 (de) Durchführungstülle
DE10085449T1 (de) Fixiervorrichtung
FI20010922A (fi) Uusia vektoreita
DE50008770D1 (de) Winkelschleiferschutzhaube
DE60129561D1 (de) Motorabdeckung
DE60124109D1 (de) Enthaarungsmittel
IT250181Y1 (it) Custodia perfezionata per rivoltella
DE60143786D1 (de) Organosiliziumverbindung
NO20024322D0 (no) Sekvens
DE60038434D1 (de) Schutzkonfiguration für Flachkabel
DE60127202D1 (de) Organosiliziumverbindungen
ATA9012000A (de) Wasserspeicher
DE60126819D1 (de) Lanzette für hautstiche
DE60135621D1 (de) Fixiergerät
DE60008492D1 (de) Griffanordnung für koffer

Legal Events

Date Code Title Description
8364 No opposition during term of opposition